Literature DB >> 21609720

Differential reduction of HCN channel activity by various types of lipopolysaccharide.

Udo Klöckner1, Uwe Rueckschloss, Claudia Grossmann, Henning Ebelt, Ursula Müller-Werdan, Harald Loppnow, Karl Werdan, Michael Gekle.   

Abstract

Recently it was shown that lipopolysaccharide (LPS) impairs the pacemaker current in human atrial myocytes. It was speculated that reduced heart rate variability (HRV), typical of patients with severe sepsis, may partially be explained by this impairment. We evaluated the effect of various types of LPS on the activity of human hyperpolarization-activated cyclic nucleotide-gated channel 2 (hHCN2) expressed in HEK293 cells, and on pacemaker channels in native murine sino-atrial node (SAN) cells, in order to determine the structure of LPS necessary to modulate pacemaker channel function. Application of LPS caused a robust inhibition of hHCN2-mediated current (I(hHCN2)) owing to a negative shift of the voltage dependence of current activation and to a reduced maximal conductance. In addition, kinetics of channel gating were modulated by LPS. Pro-inflammatory LPS-types lacking the O-chain did not reduce I(hHCN2), whereas pro-inflammatory LPS-types containing the O-chain reduced I(hHCN2). On the other hand, a detoxified LPS without inflammatory activity, but containing the O-chain reduced I(hHCN2). Similar observations were made in HEK293 cells expressing hHCN4 and in murine SAN cells. This mechanistic analysis showed the novel finding that the O-chain of LPS is required for reduction of HCN channel activity. In the clinical situation the observed modulation of HCN channels may slow down diastolic depolarization of pacemaker cells and, hence, influence heart rate variability and heart rate.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21609720     DOI: 10.1016/j.yjmcc.2011.05.004

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

1.  Inhibition of cardiac pacemaker channel hHCN2 depends on intercalation of lipopolysaccharide into channel-containing membrane microdomains.

Authors:  Udo Klöckner; Uwe Rueckschloss; Claudia Grossmann; Saskia Matzat; Katja Schumann; Henning Ebelt; Ursula Müller-Werdan; Harald Loppnow; Karl Werdan; Michael Gekle
Journal:  J Physiol       Date:  2013-12-23       Impact factor: 5.182

Review 2.  [Septic shock and septic cardiomyopathy].

Authors:  H Ebelt; K Werdan
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-02-02       Impact factor: 0.840

3.  Lipopolysaccharide prolongs action potential duration in HL-1 mouse cardiomyocytes.

Authors:  Robert Wondergem; Bridget M Graves; Chuanfu Li; David L Williams
Journal:  Am J Physiol Cell Physiol       Date:  2012-08-15       Impact factor: 4.249

4.  Cyclic dinucleotides bind the C-linker of HCN4 to control channel cAMP responsiveness.

Authors:  Marco Lolicato; Annalisa Bucchi; Cristina Arrigoni; Stefano Zucca; Marco Nardini; Indra Schroeder; Katie Simmons; Marco Aquila; Dario DiFrancesco; Martino Bolognesi; Frank Schwede; Dmitry Kashin; Colin W G Fishwick; A Peter Johnson; Gerhard Thiel; Anna Moroni
Journal:  Nat Chem Biol       Date:  2014-04-28       Impact factor: 15.040

Review 5.  Advances in the management of heart failure: the role of ivabradine.

Authors:  Ursula Müller-Werdan; Georg Stöckl; Karl Werdan
Journal:  Vasc Health Risk Manag       Date:  2016-11-17

6.  Heart rate variability as predictor of mortality in sepsis: A prospective cohort study.

Authors:  Fábio M de Castilho; Antonio Luiz P Ribeiro; José Luiz P da Silva; Vandack Nobre; Marcos R de Sousa
Journal:  PLoS One       Date:  2017-06-27       Impact factor: 3.240

Review 7.  Intracardiac origin of heart rate variability, pacemaker funny current and their possible association with critical illness.

Authors:  Vasilios E Papaioannou; Arie O Verkerk; Ahmed S Amin; Jaques M T de Bakker
Journal:  Curr Cardiol Rev       Date:  2013-02-01

8.  I(f) blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytes.

Authors:  Susanne Scheruebel; Chintan N Koyani; Seth Hallström; Petra Lang; Dieter Platzer; Heinrich Mächler; Karl Lohner; Ernst Malle; Klaus Zorn-Pauly; Brigitte Pelzmann
Journal:  J Mol Cell Cardiol       Date:  2014-02-25       Impact factor: 5.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.